Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rezolute Inc (RZLT)

Rezolute Inc (RZLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,180
  • Shares Outstanding, K 40,128
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,790 K
  • 60-Month Beta 1.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.16
Trade RZLT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.35
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.22 +48.99%
on 04/04/24
3.69 -10.30%
on 04/22/24
+0.93 (+39.08%)
since 04/03/24
3-Month
0.92 +259.82%
on 02/05/24
3.69 -10.30%
on 04/22/24
+2.26 (+215.24%)
since 02/02/24
52-Week
0.72 +359.72%
on 11/30/23
3.69 -10.30%
on 04/22/24
+1.16 (+53.95%)
since 05/03/23

Most Recent Stories

More News
Rezolute, Inc. (RZLT) Upgraded to Buy: Here's Why

Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

RZLT : 3.31 (+11.45%)
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...

RZLT : 3.31 (+11.45%)
Rezolute to Host Corporate Update Call on May 4, 2022

Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET...

RZLT : 3.31 (+11.45%)
Rezolute, Inc. Announces Closing of Registered Direct Offering

REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...

RZLT : 3.31 (+11.45%)
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...

RZLT : 3.31 (+11.45%)
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting...

RZLT : 3.31 (+11.45%)
Rezolute Joins the Rare Disease Company Coalition

Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases...

RZLT : 3.31 (+11.45%)
Rezolute (RZLT) Posts Positive Data From Congenital HI Study

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.

VRTX : 401.08 (+0.23%)
ATHX : 0.0135 (-33.50%)
RZLT : 3.31 (+11.45%)
KLDO : 0.0001 (unch)
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism

The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral...

RZLT : 3.31 (+11.45%)
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Phase 2 proof-of-concept study anticipated in 2H 2022...

RZLT : 3.31 (+11.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rezolute, Inc. is a biopharmaceutical company specializing in the development of drug therapies for metabolic and orphan diseases. The Company's products include AB101, RZ358, RZ402 and RZ602 which are in clinical stage. Rezolute, Inc., formerly known as AntriaBio, Inc., is based in LOUISVILLE, United...

See More

Key Turning Points

3rd Resistance Point 3.87
2nd Resistance Point 3.62
1st Resistance Point 3.47
Last Price 3.31
1st Support Level 3.07
2nd Support Level 2.82
3rd Support Level 2.67

See More

52-Week High 3.69
Last Price 3.31
Fibonacci 61.8% 2.56
Fibonacci 50% 2.20
Fibonacci 38.2% 1.85
52-Week Low 0.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar